Agreed. But although I don't think I have EVER before, for any market time or market area, said "it's different this time", it is actually true that biotech advancement is making the largest strides I've seen in my decade+ of watching this stuff. Accordingly let me put this out there as the start of an interesting thread.
Examples of the move forward:
1) Onc - commonplace to see HRs under 0.40. 5 years ago - almost never.
2) Whole new indications - e.g. the Intercept NASH results
3) Great efficacy in other big indications: T2D High Trig (ISIS' APOC3), lipid lowering of dramatic amounts (PCSK9), ... .
And I would suggest that this is the product of really better understanding the genome and, importantly, how it plays together. Perhaps the intial spurt when Mabs first happened was just as dramatic? (Before my time - hence the question mark.)